MAZE: Promising phase II results in AMKD and PKU, with pivotal trials and key data readouts ahead
Three clinical programs are advancing, with MZE829 showing promising phase II results in AMKD and broad potential across patient subgroups. Key data readouts and trial initiations are expected over the next two years, supported by strong financial resources and ongoing industry collaboration.Based…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.